Anzeige
Mehr »
Dienstag, 08.07.2025 - Börsentäglich über 12.000 News
750-Millionen-Euro-Finanzier verstärkt Forge - Sichtbares Gold befeuert Exploration
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DMHM | ISIN: US00289Y2063 | Ticker-Symbol: PCJ
Tradegate
07.07.25 | 10:33
4,920 Euro
+0,41 % +0,020
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ABEONA THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
ABEONA THERAPEUTICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
4,7204,94011:17
4,7204,94011:17

Aktuelle News zur ABEONA THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoAbeona Closes $155 Mln PRV Sale, Strengthens Cash Position Ahead Of ZEVASKYN Launch3
MiAbeona sells Rare Pediatric Disease PRV for $155M2
MiAbeona Therapeutics schließt Verkauf von Priority Review Voucher für 155 Millionen US-Dollar ab5
MiAbeona therapeutics closes sale of priority review voucher for $155 million1
MiAbeona Therapeutics Inc.: Abeona Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $155 Million1
ABEONA THERAPEUTICS Aktie jetzt für 0€ handeln
MiABEONA THERAPEUTICS INC. - 8-K, Current Report8
01.07.Beacon Therapeutics licenses Abeona's AAV204 capsid for retinal therapies4
01.07.Abeona Therapeutics Inc.: Abeona Therapeutics Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy153CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that Beacon Therapeutics, an ophthalmic gene therapy company and Syncona portfolio company, has...
► Artikel lesen
01.07.Abeona Therapeutics Inc.: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)45CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
► Artikel lesen
30.06.Abeona Therapeutics added to U.S. Small-cap Russell 2000 and Russell 3000 Indexes1
30.06.Abeona Therapeutics Inc.: Abeona Therapeutics added to Membership of U.S. Small-cap Russell 2000 Index and Broad-market Russell 3000 Index5
24.06.Abeona Therapeutics Inc.: Abeona Therapeutics Announces Publication in The Lancet of Phase 3 VIITAL Study Data in Recessive Dystrophic Epidermolysis Bullosa4
04.06.Abeona Therapeutics auf Jefferies-Konferenz: Vielversprechender Start von ZivaSkin 6
02.06.Oppenheimer assumes coverage on Abeona Therapeutics stock9
02.06.Abeona Therapeutics Inc.: Abeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)89CLEVELAND, June 02, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity...
► Artikel lesen
22.05.DelveInsight Business Research, LLP: ZEVASKYN Approval Positions Abeona as Emerging Player in Dystrophic Epidermolysis Bullosa Market | DelveInsight366Approximately a year after the FDA rejected its previous approval submission, Abeona announced that the agency had approved ZEVASKYN, its autologous cell-based gene therapy for both adult...
► Artikel lesen
19.05.ABEONA THERAPEUTICS INC. - 8-K, Current Report4
16.05.Abeona targets treating 10-14 ZEVASKYN patients in 2025 while securing $155M PRV sale to extend runway7
15.05.Abeona Therapeutics GAAP EPS of -$0.24 beats by $0.124
15.05.ABEONA THERAPEUTICS INC. - 10-Q, Quarterly Report1
Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1